ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Akeso, Takeda, Pfizer

ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Akeso, Takeda, Pfizer
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 30+ key pharma and biotech companies are working on 30+ pipeline drugs in the ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the ALK-positive Non-Small Cell Lung Cancer Market. 

The ALK-positive Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial, regulatory, and ALK-positive Non-Small Cell Lung Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging ALK-positive Non-Small Cell Lung Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for ALK-positive Non-Small Cell Lung Cancer treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different ALK-positive Non-Small Cell Lung Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major ALK-positive Non-Small Cell Lung Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the ALK-positive Non-Small Cell Lung Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the ALK-positive Non-Small Cell Lung Cancer therapeutics market.

ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Therapeutics Landscape

Anaplastic Lymphoma Kinase (ALK), is a CD receptor (CD246) that plays a significant role in the development of neurons. The ALK gene products are known to promote cell growth/proliferation and inhibit apoptosis at baseline. There are several therapies approved under this category, such as ALUNBRIG (brigatinib), ZYKADIA (ceritinib), XALKORI (crizotinib), and ALECTINIB. Apart from this, LORBRENA (lorlatinib) is another therapy available for the ALK-positive NSCLC patient pool.

There are approx. 30+ key companies developing the therapies for ALK-positive Non-Small Cell Lung Cancer. Currently,  Betta Pharmaceuticals/Xcovery, Chia Tai Tianqing Pharmaceutical Group, Merck, and Pfizer are among the key pharma and biotech giants leading the ALK-positive Non-Small Cell Lung Cancer therapeutics landscape with their drug candidates in the mid to advanced stage of clinical development.

ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Companies Actively Working in the Therapeutic Market Include:

  • GlaxoSmithKline

  • Novartis

  • AstraZeneca

  • Pfizer Inc.

  • F. Hoffmann-La Roche Ltd.

  • Merck

  • Suzhou Zelgen Biopharmaceuticals Co., Ltd

  • Ariad Pharmaceutica

  • Takeda

  • Chia Tai Tianqing Pharmaceutical Group

  • Akeso

And Many Others

Emerging and Marketed ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Drugs Covered in the Report Include:

  • Ensartinib: Betta Pharmaceuticals/Xcovery

Ensartinib is a potential best-in-class compound for the first-line treatment of anaplastic lymphoma kinase (ALK)–positive non-small cell lung cancer (NSCLC). Ensartinib has shown promising clinical activity in patients with ALK-positive NSCLC in a phase 1/2 trial. 

  • TQ-B3139 – Chia Tai Tianqing Pharmaceutical Group

TQ-B3139 is an orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. 

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and ALK-positive Non-Small Cell Lung Cancer Companies Working in the Market @

https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight

Analysis of Emerging ALK-positive Non-Small Cell Lung Cancer Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

ALK-positive Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Intramuscular

  • Intratumoral

  • Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

  • Gene therapies

  • Bispecific antibodies

  • Immunotherapies

  • Monoclonal antibodies

  • Small molecules

Learn How the ALK-positive Non-Small Cell Lung Cancer Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. ALK-positive Non-Small Cell Lung Cancer Treatment Patterns

4. ALK-positive Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. ALK-positive Non-Small Cell Lung Cancer Late Stage Products (Phase-III)

7. ALK-positive Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)

8. ALK-positive Non-Small Cell Lung Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. ALK-positive Non-Small Cell Lung Cancer Discontinued Products

13. ALK-positive Non-Small Cell Lung Cancer Product Profiles

14. Major ALK-positive Non-Small Cell Lung Cancer Companies in the Market

15. Key Products in the ALK-positive Non-Small Cell Lung Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. ALK-positive Non-Small Cell Lung Cancer Unmet Needs

18. ALK-positive Non-Small Cell Lung Cancer Future Perspectives

19. ALK-positive Non-Small Cell Lung Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Diabetes Market

“Diabetes Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Diabetes market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Diabetes market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology